Dubai: A leading and exciting pharma hotspot

AstraZeneca recently has announced the results of the clinical trials POSEIDON which included the study of a combination of drugs Imfinzi (durvalumab) and tremelimumab with chemotherapy in lung cancer. Imfinzi is a human monoclonal antibody which blocks the interaction of PD-L1 with PD-1 by binding itself with ...

Rapt Therapeutics files for IPO at $75M Rapt Therapeutics, based in the US, filed to raise to $75 million in its IPO. This had come after five months when the company had retitled itself, which was earlier known as Flx Bio and after three months, it had filed its initial S-1 form with the hope to gain $86 millio...

Liver Cancer incidence is not as high as the incidence of breast or lung cancer. However, rising diagnosis rates reveal another story. According to a survey, Liver cancer has become an increasing cause of deaths in Americans. According to the American Institute for Cancer Research, Liver cancer is the fifth most co...

Recently the U.S. Food and Drug Administration has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. A 50 mg, twice daily oral pill, Ibsrela is a small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen...

NAFLD is one of the leading causes of liver damage in the younger population. The increasing NAFLD prevalence runs parallel with the increasing trends in obesity among people. However, this does not imply that the lean population does not get affected by it. Global NAFLD prevalence is estimated to be as high as One...

GNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecul...